论文部分内容阅读
目的探讨舍曲林辅助治疗伴有抑郁症状的青少年支气管哮喘的疗效及安全性。方法将符合纳入标准的77例青少年支气管哮喘患者随机分为两组:治疗组40例,在常规治疗基础上加服舍曲林,对照组37例,加服安慰剂,疗程12周。治疗后的第6、12周末进行疗效及安全性评定。结果治疗12周后,治疗组抑郁治疗有效率(72.5%)及哮喘治疗有效率(95.0%)均优于对照组(分别为37.8%、72.9%),且差异有统计学意义(P<0.05)。2组不良反应均较轻,SERS各因子发生率及总分比较差异均无统计学意义(P>0.05)。结论舍曲林对治疗伴有抑郁症状的青少年支气管哮喘患者有效,且安全性好。
Objective To investigate the efficacy and safety of sertraline in the treatment of adolescent bronchial asthma with depressive symptoms. Methods A total of 77 adolescents with bronchial asthma who met the inclusion criteria were randomly divided into two groups: 40 in the treatment group, plus sertraline on the basis of routine treatment, and 37 in the control group, plus placebo for 12 weeks. After the treatment of the first 6,12 weekend efficacy and safety assessment. Results After 12 weeks of treatment, the effective rate of depression (72.5%) and the effective rate of asthma treatment (95.0%) in the treatment group were better than those in the control group (37.8% and 72.9% respectively) (P <0.05 ). There were no significant differences in the incidence of SERS and the total score between the two groups (P> 0.05). Conclusion Sertraline is effective and safe for treating juvenile asthma with depressive symptoms.